Literature DB >> 1388249

Lipoprotein(a) predicts the risk of thrombogenic complications in nephrotic syndrome.

T Fujita, E Saito, H Ohi, T Yasugi, M Hatano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1388249     DOI： 10.1159/000186854

Source DB:  PubMed          Journal:  Nephron        ISSN： 1660-8151            Impact factor:   2.847


× No keyword cloud information.
  5 in total

1.  Clinical implications of elevated lipoprotein(a).

Authors:  A von Eckardstein; G Assmann
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

2.  Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity.

Authors:  Neşe Ozkayin; Sevgi Mir; Kaan Kavakli
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

3.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

Review 4.  Lipoprotein(a): new insights into an atherogenic lipoprotein.

Authors:  W Bartens; C Wanner
Journal:  Clin Investig       Date:  1994-08

5.  A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis.

Authors:  I Missala; U Kassner; E Steinhagen-Thiessen
Journal:  Int J Rheumatol       Date:  2012-12-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.